BioSpace News Archive

Advisory Council launches its online consultations on how to move forward toward a national pharmacare

FinancialBuzz.com News Commentary

Technavio has announced their latest pipeline analysis report on the Behcet’s syndrome market.

New portal makes life easier for doctors

Tour will bring interactive exhibit across Canada offering Canadians the opportunity to learn the facts about cannabis and encourage youth to pursue healthy activities, rather than using cannabis.

At ThoughtSpot 2018, leaders announce program enhancements that will help pharmacists thrive today and in the future

The American Red Cross has elected to its National Board of Governors Johnny C. Taylor, Jr., President and Chief Executive Officer of the Society for Human Resource Management.

The safety and efficacy of Essure have not changed [20-July-2018] WHIPPANY, N.J., July 20, 2018 /PRNewswire/ -- Bayer has made a business decision to voluntarily discontinue sales and distribution of the Essure ® System for Permanent Birth Control in the United States after December 31, 2018. This decision is based on a decline in U.S. sales of Essure

From battlefield to bedside, these rugged and reliable solutions have ushered in a new era of helping clinicians bring ultrasound to any patient, anywhere, anytime.

The U.S. Food and Drug Administration was notified by Bayer that the Essure permanent birth control device will no longer be sold or distributed after December 31, 2018.